The significant EPS beat, combined with de-risked clinical pathways for two potential best-in-class assets and a multi-year cash runway, suggests meaningful value inflection. Traders should monitor upcoming Phase 2b initiation for VIS-101 and potential Phase 3 start for givastomig as key catalysts.
Price Chart
Executive Summary
NovaBridge Biosciences reported a net loss of $46.3M for FY 2025 with EPS of $(0.21), a significant improvement from $(0.27) in the prior year, beating consensus EPS of $(0.23) by 45.5%. The company highlighted major clinical progress in its two lead programs, givastomig and VIS-101, and maintains a strong cash position of $210.8M supporting operations into 2028.
Key Financial Metrics
Key Facts
- Reported net loss attributable to NovaBridge of $46.3M for FY 2025 (EPS $(0.21)), beating consensus estimate of $(0.23)
- Cash, cash equivalents, and short-term investments totaled $210.8M as of December 31, 2025, sufficient to fund operations through 2028
- Givastomig showed 75% objective response rate in Phase 1b gastric cancer trial and potential eligibility for FDA Accelerated Approval
- VIS-101 demonstrated rapid, robust, and durable responses in wet-AMD with ~two-thirds of patients retreatment-free at 4 months
- Company initiated underwritten offering in 2025, raising $61.7M net proceeds
Financial Impact
EPS beat by $0.02 (45.5% better than expected), with strong cash position of $210.8M supporting operations through 2028
Risk Factors
- High R&D expenses increased to $62.9M in 2025 from $21.8M in 2024, driven by IPR&D charges
- Forward-looking statements about clinical timelines and regulatory pathways are subject to significant uncertainty
- Company remains pre-revenue with no near-term commercialization potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269679 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers